November 2021 • PharmaTimes Magazine • 4-5

Image

Contents

Features

Is this pharma’s chance to shine?

Exploring the proposed changes to NICE’s approach to health technology assessment

A look at the digital landscape and rare cancer patients

Transforming Beyond the Pill from optional industry extra to essential market opportunity

Analysis

What makes trade secrets different from other types of IP protection?

Navigating the differing requirements in the EU and US

What should the big pharma brands do next?

Why it is crucial to invest in the progress of the clinical research workforce

Responding to the explosion of mobile & digital health across international markets

How can the healthcare industry communicate with Gen Z adolescents?

SmartPeople

PharmaTimes talks to argenx’s Vice President, Head of Medical Affairs and country manager, UK and Ireland